Premium
Human CMV‐IGIV (CytoGam®) neutralizes human cytomegalovirus (HCMV) infectivity and prevents intracellular signal transduction after HCMV exposure
Author(s) -
Andreoni K.A.,
Wang X.,
Huong S.M.,
Huang E.S.
Publication year - 2001
Publication title -
transplant infectious disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.69
H-Index - 67
eISSN - 1399-3062
pISSN - 1398-2273
DOI - 10.1034/j.1399-3062.2001.00005.x
Subject(s) - human cytomegalovirus , infectivity , extracellular , virology , intracellular , cytomegalovirus , biology , signal transduction , viral entry , transduction (biophysics) , glycoprotein , virus , microbiology and biotechnology , viral replication , herpesviridae , viral disease , biochemistry
Pretreatment of human cytomegalovirus (HCMV) with human hyperimmune globulin (CytoGam®) in human embryonic lung (HEL) fibroblast culture showed successful inhibition of infectivity, and decreased extracellular viral titers and extracellular viral DNA. CytoGam® prevented HCMV from inducing intracellular activation of NF‐κB, Sp‐1, and PI3‐K signaling pathways and the production of immediate‐early (IE), early (E), and late (L) viral proteins. CytoGam® neutralization of HCMV in this cell culture model prevented the earliest known signal transduction events (NF‐κB, Sp‐1, PI3‐K activation) after viral specific glycoproteins bind to their cognate cell membrane receptors, suggesting that this agent contains highly effective neutralizing antibodies against HCMV.